 |
|
Multiple Squamous Cell Carcinomas of the Skin After Therapy With Sorafenib Combined With Tipifarnib
David S. Hong, MD;
Srini B. Reddy, MD;
Victor G. Prieto, MD;
John J. Wright, MD, PhD;
Nizar M. Tannir, MD;
Philip R. Cohen, MD;
A. Hafeez Diwan, MD, PhD;
Harry L. Evans, MD;
Razelle Kurzrock, MD
Arch Dermatol. 2008;144(6):779-782.
Background Keratoacanthomas, as well as an actinic keratosis progressing to squamous cell cancer, have been reported in patients who were treated with sorafenib, a multikinase inhibitor known to suppress the actions of Raf kinase and vascular endothelial growth factor receptor.
Observations We describe a 70-year-old white woman with metastatic renal cell carcinoma who was treated with a combination of sorafenib and tipifarnib (a farnesyltransferase inhibitor). She had no history of skin cancer. However, within 3 months after starting this therapy, she developed 3 erythematous nodules on her legs. Pathologic examination showed deeply invasive, well-differentiated squamous cell carcinomas. The tumors were excised, and sorafenib-tipifarnib treatment was discontinued. No new lesions have developed to date.
Conclusions Targeted agents, such as sorafenib and tipifarnib, are increasingly being used in the management of visceral malignant neoplasms. A temporal relationship was observed between the initiation of the targeted treatments and the emergence of these cutaneous cancers. Further study of the mechanisms responsible for the rapid appearance of squamous cell cancers in this setting may provide insights into the pathogenesis of skin tumors.
Author Affiliations: Phase I Program, Department of Investigational Cancer Therapeutics, Division of Cancer Medicine (Drs Hong, Reddy, and Kurzrock), and Departments of Pathology (Drs Prieto, Diwan, and Evans), Dermatology (Drs Prieto and Diwan), and Genitourinary Medical Oncology (Dr Tannir), University of Texas M. D. Anderson Cancer Center, Houston; National Cancer Institute, Bethesda, Maryland (Dr Wright); and Departments of Dermatology, University of Houston Health Center (Dr Cohen) and University of Texas–Houston Medical School (Dr Cohen).
 CiteULike  Connotea  Delicious  Digg  Facebook  Reddit  Technorati  Twitter
What's this?
RELATED ARTICLE
This Month in Archives of Dermatology
Arch Dermatol. 2008;144(6):720.
FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Targeted Therapies for Renal Cell Carcinoma: Review of Adverse Event Management Strategies
Eisen et al.
JNCI J Natl Cancer Inst 2012;104:93-113.
ABSTRACT
| FULL TEXT
Skin Tumors Induced by Sorafenib; Paradoxic RAS-RAF Pathway Activation and Oncogenic Mutations of HRAS, TP53, and TGFBR1
Arnault et al.
Clin. Cancer Res. 2012;18:263-272.
ABSTRACT
| FULL TEXT
Activity of Sorafenib in Recurrent Ovarian Cancer and Primary Peritoneal Carcinomatosis: A Gynecologic Oncology Group Trial
Matei et al.
JCO 2011;29:69-75.
ABSTRACT
| FULL TEXT
Spiny Follicular Hyperkeratosis Eruption: A New Cutaneous Adverse Effect of Sorafenib
Franck et al.
JCO 2010;28:e640-e642.
FULL TEXT
Selective and Potent Raf Inhibitors Paradoxically Stimulate Normal Cell Proliferation and Tumor Growth
Carnahan et al.
Molecular Cancer Therapeutics 2010;9:2399-2410.
ABSTRACT
| FULL TEXT
Treatment with Tyrosine Kinase Inhibitors for Patients with Differentiated Thyroid Cancer: the M. D. Anderson Experience
Cabanillas et al.
J. Clin. Endocrinol. Metab. 2010;95:2588-2595.
ABSTRACT
| FULL TEXT
Phase I Trial of a Combination of the Multikinase Inhibitor Sorafenib and the Farnesyltransferase Inhibitor Tipifarnib in Advanced Malignancies
Hong et al.
Clin. Cancer Res. 2009;15:7061-7068.
ABSTRACT
| FULL TEXT
Keratoacanthomas and Squamous Cell Carcinomas in Patients Receiving Sorafenib
Arnault et al.
JCO 2009;27:e59-e61.
FULL TEXT
|
